Welcome to our dedicated page for Centene Del SEC filings (Ticker: CNC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Centene Corporation filings document operating and financial disclosures for a government-focused managed care company. Form 8-K reports furnish quarterly results press releases, GAAP and adjusted EPS guidance, non-GAAP financial measure disclosures, conference-related Regulation FD updates and material-event reports tied to company performance.
Centene's proxy and governance filings cover annual meeting matters, board and executive compensation disclosures, equity awards, officer appointments and related corporate governance topics. Other filings address material agreements, forward-looking-statement disclosures and formal exhibits filed or furnished with the SEC.
Centene Corporation’s Secretary & General Counsel Christopher Koster reported a tax-related share disposition. On March 15, 2026, 9,087 shares of common stock were withheld at $34.45 per share to cover taxes upon vesting of previously granted restricted stock units.
After this withholding, Koster directly holds 352,835.617 shares of Centene common stock, plus 100 shares indirectly through his spouse. His ownership also includes 229,874 restricted and performance stock units that remain subject to vesting conditions.
Koster’s remaining equity incentives include a performance stock option for 15,690 shares at an exercise price of $81.85 per share that may become exercisable if Centene’s stock trades at $100 or more for 20 consecutive days, as well as 3,015.544 phantom stock units payable in cash or other non-company securities at or after his termination or another elected date.
Centene Corp’s Corporate Controller and Chief Accounting Officer, Katie Casso, reported a routine tax-withholding transaction related to equity compensation. On March 15, 2026, 3,359 shares of common stock were withheld at $34.45 per share to cover taxes when previously granted restricted stock units vested. This was not an open-market sale. After the withholding, she directly owns 109,776 shares of common stock, and a footnote states her ownership also includes 71,740 unvested restricted and performance stock units reported at target performance.
Centene Corporation’s Chief Financial Officer Andrew Lynn reported a routine tax-withholding transaction. On March 15, 2026, 15,241 shares of Centene common stock were withheld at $34.45 per share to cover taxes upon vesting of previously reported restricted stock units. After this, he directly owns 747,989.48 shares, and this ownership includes 448,650 restricted stock units and performance stock units subject to future vesting. He also holds a performance stock option covering 13,449 underlying shares at an exercise price of $81.85 per share, expiring on December 15, 2031, which may become exercisable if Centene’s stock trades at or above $100 for 20 consecutive trading days on or after the third anniversary of the December 15, 2021 grant.
Centene Corporation plans to present at the Barclays 28th Annual Global Healthcare Conference and, during that presentation, expects to reaffirm its 2026 full year earnings guidance. The Company continues to project GAAP diluted EPS of greater than $1.98 and adjusted diluted EPS of greater than $3.00, highlighting both reported and non-GAAP performance measures.
Centene also delivered a notice of partial redemption for $1,000,000,000 aggregate principal amount of its 4.25% Notes due December 15, 2027. After the March 25, 2026 redemption date, approximately $1,186,664,000 of these notes will remain outstanding, and the redeemed notes will be paid at 100% of principal plus accrued interest.
Centene Corporation filed an update stating that senior management will meet with investors during the week of February 23, 2026 and plans to reaffirm its previously issued 2026 full-year guidance. The Company continues to expect GAAP diluted EPS of greater than $1.98 and adjusted diluted EPS of greater than $3.00, consistent with guidance provided on February 6, 2026.
Centene explains that it uses non-GAAP metrics, including adjusted EPS, to evaluate core performance, plan operations and determine incentive compensation, while urging investors to review GAAP results alongside these measures. The filing also includes extensive forward-looking statement cautions describing regulatory, economic, operational, and contractual risks that could cause actual results to differ from guidance.
Centene Corporation reported a sharp swing to a GAAP net loss of $6.7 billion in 2025, driven mainly by large non-cash impairment charges. The loss equated to diluted EPS of $(13.53), compared with earnings of $6.31 per share in 2024.
Adjusting for goodwill and intangible impairments, divestiture-related items and tax effects, adjusted net earnings were $1.0 billion, or $2.08 in adjusted diluted EPS, down from $7.17 in 2024. Total revenues reached $194.8 billion, with operating cash flow of $5.1 billion, reflecting the scale of its Medicaid, Medicare, Marketplace and specialty operations.
Centene ended 2025 with 27.6 million members and remains the largest U.S. Medicaid and Marketplace insurer and the largest stand‑alone Medicare Part D plan sponsor. However, management highlights rising medical cost trends and major policy changes, including the One Big Beautiful Bill Act, IRA-driven Medicare Part D redesign and Marketplace rule shifts, as key uncertainties that could pressure margins and membership mix over the next several years.
AQR Capital Management, LLC and AQR Capital Management Holdings, LLC reported a passive ownership stake in Centene Corporation. The firms beneficially own 31,798,738 shares of Centene common stock, representing 6.47% of the outstanding class as of the reported date. All of these shares are reported with shared voting and shared dispositive power, with no sole voting or dispositive authority. The reporting persons state that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Centene.
Centene Corp’s Corporate Controller and Chief Accounting Officer reported a new stock award and corrected prior holdings. On 01/26/2026, the officer acquired 26,036 shares of Centene common stock at $0 as equity compensation, bringing beneficial ownership to 113,135 shares held directly.
The award consists of 13,018 restricted stock units that vest in three annual installments beginning on March 15, 2027, and 13,018 performance stock units reported at target. The performance stock units are scheduled to vest on March 15, 2029, with the actual number ranging from 0% to 200% of target based on Centene’s stock price performance for the final 20 trading days of 2025 compared to the final 60 trading days of 2028. The amendment also removes 9,236 shares from total holdings, reflecting performance stock units for the period ending December 31, 2025 that did not meet vesting criteria as determined on January 26, 2026.
Centene Corp’s Corporate Controller and Chief Accounting Officer reported a new stock award and corrected prior holdings. On 01/26/2026, the officer acquired 26,036 shares of Centene common stock at $0 as equity compensation, bringing beneficial ownership to 113,135 shares held directly.
The award consists of 13,018 restricted stock units that vest in three annual installments beginning on March 15, 2027, and 13,018 performance stock units reported at target. The performance stock units are scheduled to vest on March 15, 2029, with the actual number ranging from 0% to 200% of target based on Centene’s stock price performance for the final 20 trading days of 2025 compared to the final 60 trading days of 2028. The amendment also removes 9,236 shares from total holdings, reflecting performance stock units for the period ending December 31, 2025 that did not meet vesting criteria as determined on January 26, 2026.
Centene Corp’s Chief People Officer reported an equity award of 74,311 shares of common stock at $0 per share. After this grant, the officer beneficially owns 131,007 shares directly.
The new award includes 29,724 restricted stock units that vest in three annual installments beginning on March 15, 2027, plus 44,587 performance stock units reported at target. The performance units can vest from 0% to 200% of target on March 15, 2029, based on Centene’s stock price performance over specified trading periods in 2025 and 2028. This amended filing removes 2,073 previously counted performance stock units that did not meet vesting criteria, and notes that current ownership also includes 47,267 previously granted restricted and performance stock units subject to vesting.
Centene Corp’s Chief People Officer reported an equity award of 74,311 shares of common stock at $0 per share. After this grant, the officer beneficially owns 131,007 shares directly.
The new award includes 29,724 restricted stock units that vest in three annual installments beginning on March 15, 2027, plus 44,587 performance stock units reported at target. The performance units can vest from 0% to 200% of target on March 15, 2029, based on Centene’s stock price performance over specified trading periods in 2025 and 2028. This amended filing removes 2,073 previously counted performance stock units that did not meet vesting criteria, and notes that current ownership also includes 47,267 previously granted restricted and performance stock units subject to vesting.
Centene Corporation’s chief operating officer reported an amended equity award on Form 4/A. On January 26, 2026, the officer received 112,823 shares of common stock at $0, lifting direct beneficial ownership to 215,638 shares.
The award includes 45,129 restricted stock units that vest in three annual installments beginning March 15, 2027, plus 67,694 performance stock units at target. Those performance units can vest between 0% and 200% on March 15, 2029 based on Centene’s stock price performance over specified 2025 and 2028 trading periods. The amendment removes 9,651 unvested performance units that did not meet vesting criteria, and ownership also reflects 80,466 previously granted restricted and performance units still subject to vesting.
Centene Corporation’s chief operating officer reported an amended equity award on Form 4/A. On January 26, 2026, the officer received 112,823 shares of common stock at $0, lifting direct beneficial ownership to 215,638 shares.
The award includes 45,129 restricted stock units that vest in three annual installments beginning March 15, 2027, plus 67,694 performance stock units at target. Those performance units can vest between 0% and 200% on March 15, 2029 based on Centene’s stock price performance over specified 2025 and 2028 trading periods. The amendment removes 9,651 unvested performance units that did not meet vesting criteria, and ownership also reflects 80,466 previously granted restricted and performance units still subject to vesting.